Tech Company Financing Transactions
TELA Bio Funding Round
On 10/31/2017, TELA Bio announced $25 million in funding from Pacira Pharmaceuticals.
Transaction Overview
Company Name
Announced On
10/31/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Pacira Pharmaceuticals (David Stack)
Proceeds Purpose
Specifically, the new injection of funds will boost the Malvern, Pennsylvania-based company's clinical and commercial efforts in the two indications of abdominal hernias and reconstruction of the abdominal wall, said TELA CEO Antony Koblish in a statement.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
1 Great Valley Pkwy. 24
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
TELA Bio (Nasdaq: TELA), a surgical reconstruction company, is driven by the desire to make a difference. Our seasoned leadership team dedicates their expertise in medical technology to transforming the soft tissue reconstruction market and making natural repair solutions more accessible to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Antony Koblish
Chief Financial Officer
Nora Brennan
Chief Medical Officer
Maarten Persenaire
Chief Technical Officer
Skott Greenhalgh
VP - Bus. Development
Paul Talmo
VP - Customer Service
Gregory Firestone
VP - Finance
Frank Conway
VP - Marketing
Stuart Henderson
VP - Operations
William Allan
VP - Operations
Michael Leonard
VP - Sales
Christopher Smith
Browse more venture capital transactions:
Prev: 10/31/2017: Solidia Technologies venture capital transaction
Next: 10/31/2017: Waycare venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs